🚀 VC round data is live in beta, check it out!
Aurobindo Pharma Valuation Multiples
Discover revenue and EBITDA valuation multiples for Aurobindo Pharma and similar public comparables like Eisai Co., Krka, Huadong Medicine, Nuvalent and more.
Aurobindo Pharma Overview
About Aurobindo Pharma
Aurobindo Pharma Ltd is a specialty and generic drug manufacturing company. It is principally engaged in the manufacturing and marketing of active pharmaceutical ingredients, generic pharmaceuticals, and related services. Its formulations target key therapeutic areas, including Central Nervous System (CNS), Antibiotics, Anti-diabetics, Cardiovascular, Anti-retroviral, Gastroenterology, Oncology, and Dermatology. The operating and reportable segments of the company are; India, the United States of America, Europe, and the Rest of the World. The company generates a majority of its revenue from its business in the United States of America.
Founded
1986
HQ
Employees
9.1K
Website
Sectors
Financials (LTM)
EV
$9B
Aurobindo Pharma Financials
Aurobindo Pharma reported last 12-month revenue of $4B and EBITDA of $742M.
In the same LTM period, Aurobindo Pharma generated $2B in gross profit, $742M in EBITDA, and $393M in net income.
Revenue (LTM)
Aurobindo Pharma P&L
In the most recent fiscal year, Aurobindo Pharma reported revenue of $4B and EBITDA of $777M.
Aurobindo Pharma expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $4B | XXX | $4B | XXX | XXX | XXX |
| Gross Profit | $2B | XXX | $2B | XXX | XXX | XXX |
| Gross Margin | 60% | XXX | 51% | XXX | XXX | XXX |
| EBITDA | $742M | XXX | $777M | XXX | XXX | XXX |
| EBITDA Margin | 20% | XXX | 21% | XXX | XXX | XXX |
| EBIT Margin | 15% | XXX | 16% | XXX | XXX | XXX |
| Net Profit | $393M | XXX | $408M | XXX | XXX | XXX |
| Net Margin | 11% | XXX | 11% | XXX | XXX | XXX |
| Net Debt | — | — | $256M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Aurobindo Pharma Stock Performance
Aurobindo Pharma has current market cap of $9B, and enterprise value of $9B.
Market Cap Evolution
Aurobindo Pharma's stock price is $14.97.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $9B | $9B | 0.5% | XXX | XXX | XXX | $0.70 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialAurobindo Pharma Valuation Multiples
Aurobindo Pharma trades at 2.4x EV/Revenue multiple, and 11.5x EV/EBITDA.
EV / Revenue (LTM)
Aurobindo Pharma Financial Valuation Multiples
As of April 19, 2026, Aurobindo Pharma has market cap of $9B and EV of $9B.
Equity research analysts estimate Aurobindo Pharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Aurobindo Pharma has a P/E ratio of 22.1x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $9B | XXX | $9B | XXX | XXX | XXX |
| EV (current) | $9B | XXX | $9B | XXX | XXX | XXX |
| EV/Revenue | 2.4x | XXX | 2.3x | XXX | XXX | XXX |
| EV/EBITDA | 11.5x | XXX | 11.0x | XXX | XXX | XXX |
| EV/EBIT | 15.5x | XXX | 14.7x | XXX | XXX | XXX |
| EV/Gross Profit | 3.9x | XXX | 4.5x | XXX | XXX | XXX |
| P/E | 22.1x | XXX | 21.3x | XXX | XXX | XXX |
| EV/FCF | 25.7x | XXX | 55.4x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Aurobindo Pharma Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Aurobindo Pharma Margins & Growth Rates
Aurobindo Pharma's revenue in the last 12 month grew by 13%.
Aurobindo Pharma's revenue per employee in the last FY averaged $0.4M, while opex per employee averaged $0.1M for the same period.
Aurobindo Pharma's rule of 40 is 32% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Aurobindo Pharma's rule of X is 50% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Aurobindo Pharma Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 13% | XXX | (3%) | XXX | XXX | XXX |
| EBITDA Margin | 20% | XXX | 21% | XXX | XXX | XXX |
| EBITDA Growth | 15% | XXX | (5%) | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 32% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 50% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.4M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | 6% | XXX | 9% | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 3% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 5% | XXX | 5% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 37% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Aurobindo Pharma Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Aurobindo Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Eisai Co. | XXX | XXX | XXX | XXX | XXX | XXX |
| Krka | XXX | XXX | XXX | XXX | XXX | XXX |
| Huadong Medicine | XXX | XXX | XXX | XXX | XXX | XXX |
| Nuvalent | XXX | XXX | XXX | XXX | XXX | XXX |
| Vaxcyte | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Aurobindo Pharma M&A Activity
Aurobindo Pharma acquired XXX companies to date.
Last acquisition by Aurobindo Pharma was on XXXXXXXX, XXXXX. Aurobindo Pharma acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Aurobindo Pharma
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialAurobindo Pharma Investment Activity
Aurobindo Pharma invested in XXX companies to date.
Aurobindo Pharma made its latest investment on XXXXXXXX, XXXXX. Aurobindo Pharma invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Aurobindo Pharma
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Aurobindo Pharma
| When was Aurobindo Pharma founded? | Aurobindo Pharma was founded in 1986. |
| Where is Aurobindo Pharma headquartered? | Aurobindo Pharma is headquartered in India. |
| How many employees does Aurobindo Pharma have? | As of today, Aurobindo Pharma has over 9K employees. |
| Is Aurobindo Pharma publicly listed? | Yes, Aurobindo Pharma is a public company listed on National Stock Exchange of India. |
| What is the stock symbol of Aurobindo Pharma? | Aurobindo Pharma trades under AUROPHARMA ticker. |
| When did Aurobindo Pharma go public? | Aurobindo Pharma went public in 2000. |
| Who are competitors of Aurobindo Pharma? | Aurobindo Pharma main competitors are Eisai Co., Krka, Huadong Medicine, Nuvalent. |
| What is the current market cap of Aurobindo Pharma? | Aurobindo Pharma's current market cap is $9B. |
| What is the current revenue of Aurobindo Pharma? | Aurobindo Pharma's last 12 months revenue is $4B. |
| What is the current revenue growth of Aurobindo Pharma? | Aurobindo Pharma revenue growth (NTM/LTM) is 13%. |
| What is the current EV/Revenue multiple of Aurobindo Pharma? | Current revenue multiple of Aurobindo Pharma is 2.4x. |
| Is Aurobindo Pharma profitable? | Yes, Aurobindo Pharma is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Aurobindo Pharma? | Aurobindo Pharma's last 12 months EBITDA is $742M. |
| What is Aurobindo Pharma's EBITDA margin? | Aurobindo Pharma's last 12 months EBITDA margin is 20%. |
| What is the current EV/EBITDA multiple of Aurobindo Pharma? | Current EBITDA multiple of Aurobindo Pharma is 11.5x. |
| What is the current FCF of Aurobindo Pharma? | Aurobindo Pharma's last 12 months FCF is $332M. |
| What is Aurobindo Pharma's FCF margin? | Aurobindo Pharma's last 12 months FCF margin is 9%. |
| What is the current EV/FCF multiple of Aurobindo Pharma? | Current FCF multiple of Aurobindo Pharma is 25.7x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.